Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Feb:196:110183.
doi: 10.1016/j.diabres.2022.110183. Epub 2022 Nov 24.

Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study

Salah Abusnana  1 , Fatheya Al Awadi  2 , Hazem Aly  3 , Alaaeldin Bashier  2 , Dinesh Kumar Dhanwal  4 , Tariq Halasa  5 , Mahir Jallo  6 , Johan Medina  5 , Sagar Singhal  3
Affiliations
Free article
Multicenter Study

Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study

Salah Abusnana et al. Diabetes Res Clin Pract. 2023 Feb.
Free article

Abstract

Aim: Investigate the effectiveness of IDegLira, a fixed-ratio combination of insulin degludec/liraglutide, in a real-world setting in patients with type 2 diabetes mellitus in the United Arab Emirates.

Methods: This non-interventional study enrolled adults switching to IDegLira from basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without concomitant oral antidiabetic drugs (OADs). Primary endpoint was change in HbA1c from baseline, assessed using a mixed model for repeated measurements.

Results: Among 263 patients (BI ± OADs, n = 206; GLP-1 RA ± OADs, n = 57), mean baseline HbA1c was 9.29 % (78 mmol/mol). After 26 weeks, HbA1c was significantly reduced (BI ± OADs, -0.83 % [-9.0 mmol/mol] and GLP-1 RA ± OADs, -1.24 % [-13.5 mmol/mol]; both p < 0.0001). Fasting plasma glucose (FPG) was significantly reduced (-39.48 mg/dL [BI ± OADs] and -82.49 mg/dL [GLP-1 RA ± OADs]; both p < 0.0001). Before treatment initiation, 3/263 patients experienced ≥ 1 severe hypoglycaemic episode and 7/263 patients experienced ≥ 1 non-severe hypoglycaemic episode compared with 1/263 patients who had ≥ 1 severe and 1/263 who had ≥ 1 non-severe episode at end of study. Body weight decreased significantly among patients switching from BI ± OADs (-1.05 kg [p < 0.0001]). Treatment was well tolerated.

Conclusions: IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.

Keywords: Glycaemic control; IDegLira; Observational study; Real world; Type 2 diabetes; United Arab Emirates.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.B. has received honoraria for lectures from many companies, including Novo Nordisk, AZ, MSD, Sanofi, Alhikma, Servier etc. M.K.J. has received research funds as a PI from Sanofi, Novo Nordisk, Johnson & Johnson, and MSD, and has received speaker honoraria as an invited speaker in continuing medical education events from Sanofi, Novo Nordisk, Novartis, and MSD. F.A. has received payment as a PI and co-PI and research coordinator. S.A. has received payment or honoraria for lectures. D.K.D. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi, Novo Nordisk, Lilly, Abbott, MSD, Servier, and Hikma Pharmaceuticals, and has received support for attending meetings and/or travel from AACE Community Dubai.

Publication types

LinkOut - more resources